Latest Acquisition News

MPower Group Limited has announced a binding agreement to sell its main renewable energy assets for approximately $19 million, reporting a net loss of $4.1 million for FY2025 largely due to discontinued operations.

Elixinol Wellness Limited reported a 12.8% revenue increase in the first half of 2025, driven by strategic acquisitions and a growing e-commerce presence, while targeting profitability by the end of the year.

Elixinol Wellness Limited reported a 12.8% increase in revenue to $7.6 million for the first half of 2025, driven by Healthy Chef and Hemp Foods Australia, alongside improved gross margins. However, integration expenses weighed on profitability, resulting in an adjusted EBITDA loss of $2.2 million.

Elixinol Wellness Limited reported a 12.8% increase in revenue to $7.64 million for the half-year ended June 2025, yet its net loss widened by 12.2% to $3.09 million, reflecting higher marketing and restructuring expenses following recent acquisitions.

MIXI Australia has secured majority voting power in PointsBet, pushing the takeover offer deadline to mid-September and setting the stage for full control.

Vinyl Group Ltd reports a striking 190% revenue increase in FY25, driven by acquisitions and organic growth, while preparing for its first EBITDA positive quarter by December 2025.

Vinyl Group Ltd reported a striking 190% revenue increase for FY2025 but remains deep in the red with a $15.8 million loss. The company’s recent acquisitions and ongoing audit spotlight a pivotal moment for its future.

Platformo Ltd reported a 38% revenue increase driven by its Malaysian software arm Biztrak, alongside a modest improvement in its half-year loss. The company continues to navigate regulatory shifts and product enhancements in a competitive software market.

DigitalX Limited posted a larger loss for FY25 despite an 18% revenue increase, driven by digital asset appreciation and a bold Bitcoin accumulation strategy.

Bridge SaaS Limited reported a remarkable 524.6% revenue jump to $7.47 million for FY25, driven by its acquisition of Brightside Disability Support & Respite. Despite this growth, the company narrowed its loss to $1.13 million but remains unprofitable.

Paradigm Biopharmaceuticals marked FY25 with the launch of its global Phase 3 trial for its osteoarthritis drug iPPS, backed by strong FDA protocol approval and a $41 million funding facility. The company also broadened its pipeline with the acquisition of Pentacoxib™, targeting early-stage OA.

Powerhouse Ventures Limited reported a striking 348.8% jump in profit after tax to $1.82 million for FY25, driven by strategic acquisitions and a robust investment portfolio. The company’s first operating cash profit and growth in net tangible assets signal a turning point in its transformation.